Education
About Us
Working with TipRanks
Follow Us
NanoViricides (NNVC)
XASE:NNVC
NNVC Stock Chart & Stats
$1.13
-$0.10(-6.54%)
At close: 4:00 PM EST
$1.13
-$0.10(-6.54%)
Day’s Range― - ―
52-Week Range$0.85 - $2.23
Previous CloseN/A
Volume409.80K
Average Volume (3M)143.34K
Market Cap
$20.95M
Enterprise Value-$5.15T
Total Cash (Recent Filing)$5.15T
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.56
Next Earnings
Nov 23, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.14
Shares Outstanding21,595,000
10 Day Avg. Volume199,739
30 Day Avg. Volume143,335
Financial Highlights & Ratios
PEG Ratio0.22
Price to Book (P/B)2.82
Price to Sales (P/S)0.00
P/FCF Ratio-2.48
Enterprise Value/Market Cap-245.88K
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit15.88M
Enterprise Value/Ebitda667.80K
Forecast
1Y Price Target
$6.00Price Target Upside430.97% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.47
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary Broad‑spectrum Nanoviricide PlatformNanoViricides’ proprietary nanoviricide platform is a structural competitive asset: a mechanism designed to bind and neutralize viruses that can be applied across multiple viral indications. A reusable platform increases R&D optionality, supports pipeline breadth, and makes partnerships or licensing more likely over the medium term.
Very Low Financial LeverageNear‑zero debt materially reduces solvency and interest‑service risk, preserving strategic flexibility to pursue development, licensing, or staged financing. This structural low‑leverage profile makes the company less vulnerable to rising rates or covenant stress and supports longer runway management decisions.
Regulatory Pathway Progress: Orphan Filings For NV‑387Orphan designation filings for NV‑387 signal a potential regulatory and commercial pathway for niche indications. Orphan status can provide fee waivers, regulatory support, and market exclusivity benefits, improving the long‑term development economics and attractiveness to partners or acquirers.
Bears Say
Pre‑revenue With Persistent Net LossesBeing pre‑revenue and consistently loss‑making is a core structural weakness: there is no commercial cash flow to fund operations or validate the technology. The company remains dependent on external financing to advance trials, increasing execution risk and making long‑term sustainability contingent on successful approvals or partnerships.
Consistent Negative Operating And Free Cash FlowPersistent operating and free cash‑flow outflows that align with net losses indicate real cash burn rather than non‑cash charges. The absence of a discernible improvement trend raises the likelihood of near‑term financing rounds, heightening dilution risk and potentially distracting management from long‑term execution priorities.
Material Decline In Shareholders' EquityA marked decline in shareholders’ equity reflects cumulative losses and prior financings, shrinking the capital buffer available for R&D and increasing reliance on external capital. This erosion heightens dilution risk, reduces financial resilience, and constrains strategic choices for advancing late‑stage development without partner funding.
NanoViricides News
NNVC FAQ
What was NanoViricides’s price range in the past 12 months?
NanoViricides lowest stock price was $0.85 and its highest was $2.23 in the past 12 months.
What is NanoViricides’s market cap?
NanoViricides’s market cap is $20.95M.
When is NanoViricides’s upcoming earnings report date?
NanoViricides’s upcoming earnings report date is Nov 23, 2026 which is in 265 days.
How were NanoViricides’s earnings last quarter?
NanoViricides released its earnings results on Nov 24, 2025. The company reported -$0.135 earnings per share for the quarter, beating the consensus estimate of -$0.18 by $0.045.
Is NanoViricides overvalued?
According to Wall Street analysts NanoViricides’s price is currently Undervalued.
Does NanoViricides pay dividends?
NanoViricides does not currently pay dividends.
What is NanoViricides’s EPS estimate?
NanoViricides’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does NanoViricides have?
NanoViricides has 21,595,000 shares outstanding.
What happened to NanoViricides’s price movement after its last earnings report?
NanoViricides reported an EPS of -$0.135 in its last earnings report, beating expectations of -$0.18. Following the earnings report the stock price went down -2.362%.
Which hedge fund is a major shareholder of NanoViricides?
Currently, no hedge funds are holding shares in NNVC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
NanoViricides
NanoViricides, Inc., a nano-biopharmaceutical research and development company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company develops Human Coronavirus Program for COVID-19 seasonal coronavirus affliction; HerpeCide Dermal Topical and Eye Drops for the treatment of shingles, PHN, chickenpox, herpes, recurrent herpes labialis, genital herpes, and ocular herpes keratitis; and HerpeCide IntraOcular Injection for viral acute retinal necrosis The company also develops FluCide Broad-Spectrum Anti-Influenza nanoviricide, which is injectable for hospitalized patients and oral for outpatients; Nanoviricide eye drops for viral diseases of the external eye; DengueCide for treatment of various types of Dengue viruses; and HIVCide, an escape-resistant anti-HIV nanoviricide. In addition, it develops other nanoviricides drug projects for treatment of different viruses and indications; and HerpeCide program expansion drug projects for different herpes viruses for different indications. NanoViricides, Inc. was founded in 2005 and is based in Shelton, Connecticut.
NNVC Stock 12 Month Forecast
Average Price Target
$6.00
▲(430.97% Upside)
Technical Analysis
CASI Pharmaceuticals
―
Enlivex
―
Akari Therapeutics
―
Moleculin Biotech
―
SAB Biotherapeutics
―
Ownership Overview
―
Insiders
3.13% Mutual Funds
0.65% Other Institutional Investors
93.84% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---